Market analysis of nebulizer


Nebulizers are mainly used to treat respiratory diseases such as asthma, bronchiectasis, pharyngitis, chronic obstructive pulmonary disease (COPD), etc. They are divided into ultrasonic nebulizers and compressed nebulizers. Compared with ultrasonic nebulizers, compressed The nebulizer has the advantages of fine and uniform drug particles, easy to penetrate into the lungs and bronchial blood vessels through breathing, and has a small amount of medication, suitable for direct absorption by the human body, speeding up the arrival of drugs to the affected area, and long service life. It is gradually replacing the ultrasonic nebulizer.

According to statistics, tens of thousands of people suffer from various respiratory diseases every year, and asthma is one of the chronic airway inflammations. Epidemiological surveys show that there are at least 300 million asthma patients in the world, but currently only 5.6% of asthma patients receiving nebulization therapy. In recent years, with the improvement of residents’ health awareness, the expansion of per capita medical expenditure and national policy support, patients’ demand for therapeutic smart micro-net nebulizer products is expanding.

From the analysis of market demand, the global inhalation therapy nebulizer market reached 6.5 billion U.S. dollars in 2019 and is expected to reach 10.1 billion U.S. dollars by 2026, with a compound annual growth rate of 6.5%. From this point of view, the scale of the compression atomizer market has grown steadily.

From the analysis of the market structure, the main importing countries of atomizers are: Germany, the United States, Italy, Japan, etc.

From the analysis of the market distribution area, it can be found that the demand in Central South is the largest, and it is also the area where the sales volume is the most concentrated; the sales volume in East China is the second. The Northwest region is currently the region with the smallest sales volume, but it is also the market with the most potential.